Keyphrases
Myoclonus
100%
Pediatric
38%
Rituximab
34%
New Onset
33%
3-year-old children
33%
Corticotropin
33%
Premanifest Huntington's Disease
33%
1H-MRS
33%
Seizure
33%
Aripiprazole
33%
Pediatric Movement Disorders
33%
Oligoclonal Bands
33%
Active Comparator
33%
Neurodegenerative Diseases
33%
Blinded Study
33%
B Cell Depletion Therapy
33%
Cerebrospinal Fluid
33%
Adrenocorticotropic Hormone
20%
Intravenous Immunoglobulin (IVIg)
17%
Putamen
16%
CSF B Cells
16%
HD Gene
16%
Striatal
16%
Clinical Examination
16%
Basal Ganglia
16%
Proton MR Spectroscopy
16%
Glutamate
16%
Clinical Variability
16%
Peripheral B Cells
16%
Corticosteroids
14%
Motor Severity
13%
Adverse Events
13%
Chemotherapy
13%
Cell Expansion
12%
Adult Patients
8%
Prolactin Levels
8%
Sleepiness
8%
Dopamine D2
8%
Headache Symptom
8%
Extrapyramidal Symptoms
8%
Control Subjects
8%
Atypical Antipsychotics
8%
Non-ambulatory
8%
Gait Ataxia
8%
Serum IgM
8%
5-hydroxytryptamine 2A Receptor
8%
Cardiac Conduction
8%
Pediatric Population
8%
Lethargy
8%
Incidental Ingestion
8%
Pharmacology, Toxicology and Pharmaceutical Science
Opsoclonus Myoclonus Syndrome
66%
Corticotropin
55%
Immunotherapy
44%
Rituximab
42%
Aripiprazole
33%
Huntington Chorea
33%
Glutamic Acid
33%
Adverse Event
28%
Immunoglobulin M
22%
Chemotherapy
15%
Opsoclonus
11%
Ataxic Gait
11%
Myoclonus
11%
Serotonin 2A Antagonist
8%
Antipsychotic
8%
Extrapyramidal Symptoms
8%
Serotonin 1A Receptor
8%
Receptor Agonist
8%
Headache
8%
Atypical Antipsychotics
8%
Dystonia
8%
Prolactin
8%
Serotonin
8%
Somnolence
8%
